AFUD brochure outlines benefits, risks of testosterone replacement

Baltimore-The American Foundation for Urologic Disease's Reproductive Health Council has developed a new patient brochure about the benefits and possible risks of testosterone replacement therapy (TRT).

Related Videos

Related Content

Advertisement

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 15th 2025

EV/pembrolizumab continues to show OS, PFS benefit vs chemotherapy in la/mUC

Hannah Clarke

“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer," says Thomas Powles, MD, PhD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

Related Content

Advertisement

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 15th 2025

EV/pembrolizumab continues to show OS, PFS benefit vs chemotherapy in la/mUC

Hannah Clarke

“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer," says Thomas Powles, MD, PhD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.